Funder
National Natural Science Foundation of China
Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University & Capital Medical University
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine
Reference57 articles.
1. Roehrborn CG (2005) Benign prostatic hyperplasia: an overview. Rev Urol 7(Suppl 9):S3–S14
2. Parsons JK, Dahm P, Kohler TS, Lerner LB, Wilt TJ (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol 204:799–804
3. Chughtai B, Forde JC, Thomas DD et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031
4. Gravas S, Cornu J, Gacci M et al (2020). European Association of Urology. Management of non-neurogenic Male LUTS. Available via: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5. Accessed 1 May, 2020
5. Xu XF, Liu GX, Zhu C et al (2020) Alpha1-blockers and 5alpha-reductase inhibitors are the most recommended drugs in treating benign prostatic hyperplasia: an evidence-based evaluation of clinical practice guidelines. Front Pharmacol 11:311
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献